ECI® Combined with Chemotherapy for the Treatment of Canine Osteosarcoma

Contact ELIAS Animal Health for information or to discuss this treatment approach.

Some clinicians have expressed interest in using ECI® as part of an integrated protocol that combines a minimized chemotherapy treatment followed by the ECI® immunotherapy. In both human and veterinary oncology, the potential for combined treatments to produce better patient outcomes has been reported.

ELIAS Animal Health is conducting prospective, open-label study to evaluate the efficacy of ECI® combined with chemotherapy to treat bone cancer in dogs. Treatment includes one to four doses of chemotherapy after amputation followed by ECI® immunotherapy. Dogs will be followed until death or lost to follow up to assess overall response rate and survival. No financial assistance is provided for participation in this study.

Study Summary

  • Eligible canine patients with newly diagnosed appendicular osteosarcoma will be treated with amputation, one to four doses of chemotherapy, and ECI®, a USDA-licensed autologous prescription product for treatment of osteosarcoma.
  • Matched controls will be selected from a published data set in the National Cancer Institute’s Canine Data Commons.
  • Kaplan-Meier analysis will be conducted with survival data compared to historical published results of dogs assigned to receive 4-dose carboplatin as treatment.

Key Inclusion Criteria

  • Patients must be newly diagnosed with appendicular osteosarcoma and must not have received prior treatment for their osteosarcoma.
  • Enrollment is required prior to amputation (affected limb must be intact).
  • Eligible patients must not have metastatic disease at the time of diagnosis.

Contact us to learn more about this study and to see if your dog or canine patient may be a good candidate.

Interim Results

Interim analysis of data from this study was presented at the 2025 ACVIM Forum on June 19, 2025. The analysis assessed dogs receiving one to four doses of chemotherapy followed 21 days later by ECI® (n=22) versus 4-dose carboplatin alone (n=22), which demonstrated one-year survival rates of 64% compared to 23%, respectively. Statistical significance (p < 0.05) was achieved with p = 0.011.

The best responses were observed in a subgroup of dogs who received one dose of carboplatin followed 21 days later by ECI® (n=14) versus 4-dose carboplatin alone (n=14), which demonstrated one-year survival rates of 71% compared to 21%, respectively. Statistical significance (p < 0.05) was achieved with p = 0.006.

Additional research from this study will be presented at two human and veterinary oncology conferences in September 2025.